Developer docs
API playgroundTry for free, no card

Search company profiles

SpiroChem AG

Full company profile

uuid000972h

Namestring
SpiroChem AG
Legal namestring
SpiroChem AG
Websiteurl
spirochem.com
Company typeenum
Private
Founded yearint
2011
Descriptiontext

SpiroChem AG is a Swiss specialty chemistry research company founded in 2011 as a spin-off of ETH Zürich, headquartered in Basel with a second R&D facility in Montreal (acquired 2023 via Cyclenium Pharma). The company operates as a Partner Research Organization (PRO), delivering integrated drug discovery and process R&D services — including computational chemistry, medicinal chemistry, synthetic chemistry, and specialized modalities (macrocycles, ADCs, degraders, radioligands, covalent inhibitors) — to biopharmaceutical companies, large pharma (Novartis, Asahi Kasei, H3 Biomedicine), biotech startups, agrochemical firms (Syngenta), and academic institutions.

The technical platform is built on proprietary infrastructure including the Hercules+ high-throughput parallel solid-phase synthesis platform, the HTE platform for reaction optimization, and SpiroBrain — a deep collective knowledge base spanning all chemistry disciplines. The company also maintains four virtual libraries (SpiroSpace: 105M+ sp3-rich molecules; MacroSpace: 229M+ macrocycles; CovSpace: 44M+ covalent compounds; GlueSpace: 95M+ CRBN-binding molecules) alongside physical screening libraries and SpiroKits. Enablement extends across solid-phase synthesis, flow chemistry, photochemistry, and electrochemistry. A granted process patent covers scalable manufacturing of bicyclo[1.1.1]pentanes (filed 2016).

The business model combines recurring FTE (Full-Time Equivalent) contracts — typically 1–6 dedicated chemists per program for 3–12+ months — with one-time compound catalog sales (13,000+ molecules via e-commerce) and hourly/project-based consulting. Go-to-market is direct enterprise sales supplemented by conference presence (EFMC, ACS, CPHI), the SpiroWebinars program, and scientific publication. Headcount has scaled from 20 (2018) to 50 (2020) to 60+ (2021) to 100+ by 2026, with the majority PhD chemists. The company is privately held, primarily built through reinvestment of profits rather than dilutive funding, and has not disclosed revenue.

Short descriptiontext

SpiroChem AG is a Swiss chemistry research partner (ETH Zürich spin-off, founded 2011) that delivers integrated drug discovery and process R&D services — medicinal chemistry, synthetic chemistry, and complex modalities — to pharma, biotech, and academia via FTE contracts and proprietary platforms.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBasel, Switzerland
HQ citystring
Basel
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract chemistry services, drug discovery research, medicinal chemistry, process R&D, custom synthesis
Industry2 codes
PRIMARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
NAICS code2 codes
  • Scientific Research and Development Services5417
  • Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)541715
SIC code1 code
  • Services-Commercial Physical & Biological Research8731
Product category
Contract Chemistry Services / Drug Discovery Research
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1FTE (Full-Time Equivalent) Service Contracts
TypeSubscription Recurring
Description

Recurring service contracts providing dedicated chemists working on client projects, typically 1-6 chemists per program for 3-12+ months duration. Core revenue stream for discovery and process R&D services.

spirochem.com
2Compound Catalog Sales
TypeOne Time License
Description

Sale of screening libraries (macrocycles, fragments, covalent fragments, scaffolds), SpiroKits, and building blocks ranging from milligram to hundred gram scale. E-commerce enabled through company website.

spirochem.com
3Consulting Services
TypeProfessional Services
Description

Expert consulting including literature analysis, SAR analysis, strategy proposals, retrosynthetic analysis, patent gap analysis, and patent filing support. Billed hourly, daily, or project-based.

spirochem.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales
Pricing details4 tiers
1Standard Shipping Rate
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Shipping fees typically 100.00 CHF per shipment; reduced fees for simultaneous orders of articles of different sales

spirochem.com
2Consulting Services
ModelOtherBilling cadencePay-as-you-go
Notes

Hourly rate, daily rate or project-based fee

spirochem.com
3FTE Contracts
ModelSubscriptionBilling cadenceMonthly
Notes

Typically 1-6 chemists per program; duration 3-12+ months; pricing based on number of chemists and project scope

spirochem.com
4Compound Catalog
ModelUnit PricingBilling cadencePay-as-you-go
Notes

13,000+ molecules available; purity >95%; scale from milligram to hundred gram; short delivery time

spirochem.com
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 8 records shown
1SpiroSpace™
Description

Virtual library providing access to more than 105 million drug-like sp3-rich molecules

spirochem.com
+7 more records
Core offering1 text field

SpiroChem AG is a Partner Research Organization (PRO) offering contract chemistry research services for drug discovery and process R&D. The company sells Full-Time Equivalent (FTE) service contracts, custom synthesis projects, compound catalog products (screening libraries and building blocks), and consulting services to biotech, pharmaceutical, agrochemical and academic clients. It also operates proprietary technology platforms (Hercules+, HTE, SpiroBrain) and virtual compound libraries (SpiroSpace, MacroSpace, CovSpace, GlueSpace) used internally and made available to clients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • Saved Cellestia CHF 0.5 million on drug development program through innovative medicinal chemistry
+1 more record
Product overview1 text field

SpiroChem AG is a pioneering research partner and Discovery Engine offering integrated drug discovery and process R&D chemistry services. The company operates a platform-plus-services model centered on its core Discovery Services (computational chemistry, medicinal chemistry, synthetic chemistry, precision delivery) and Process R&D capabilities. Key platforms include the Hercules Platform for high-throughput chemistry, HTE Platform for experimentation, and SpiroBrain for collective knowledge management. The compound portfolio includes physical screening libraries (Macrocycle Library, Fragment Library, SpiroKits, Scaffolds) and virtual libraries (SpiroSpace, MacroSpace, CovSpace, GlueSpace). The company expanded through the 2023 acquisition of Cyclenium Pharma, adding macrocycle expertise and a North American R&D facility in Montreal.

Product and service15 records
1Discovery Services
CategoryDrug discovery services
Description

Comprehensive drug discovery services including computational chemistry, medicinal chemistry, synthetic chemistry, and precision delivery, covering the hit-to-candidate journey for pharmaceutical and biotech clients.

2Process R&D
CategoryProcess chemistry services
Description

Process research and development services including route scouting, technology transfer, scale-up, impurity synthesis and identification, method development, and reference standards for pharma, biotech and CDMO clients.

3Fully Integrated Services
CategoryIntegrated drug discovery services
Description

Integrated discovery services bringing together SpiroChem's trusted research partner network supporting clients from hit validation through lead optimization to early process R&D.

4Hercules Platform
CategoryTechnology platform
Description

High-throughput chemistry platform enabling rapid parallel synthesis and broad diversity coverage for accelerated drug discovery.

5HTE Platform
CategoryTechnology platform
Description

High-throughput experimentation platform for rapid optimization of chemical reactions and reaction conditions.

6SpiroBrain
CategoryTechnology platform
Description

Deep, collective knowledge base representing SpiroChem's expertise from all chemistry disciplines, enabling problem-solving by connecting solutions across projects.

7Macrocycle Library
CategoryCompound collection
Description

Screening library of macrocyclic compounds for drug discovery, offering access to challenging biological targets with enhanced target affinity.

8Fragment Library
CategoryCompound collection
Description

Collection of over 700 fragment molecules with unique design, high sp3 content, and conformationally restricted structures for fragment-based drug discovery.

9SpiroKits
CategoryCompound collection
Description

Medicinal chemistry toolbox providing turnkey solutions to accelerate projects and foster chemical space exploration.

10SpiroSpace
CategoryVirtual compound library
Description

Virtual library of more than 105 million drug-like sp3-rich molecules, built upon SpiroChem's proprietary SPC-branded monomers combined with drug-like building blocks.

11MacroSpace
CategoryVirtual compound library
Description

Virtual collection of over 229 million distinct macrocycles with drug-like properties, created by combining three amino acids with a non-peptidic linker.

12CovSpace
CategoryVirtual compound library
Description

Virtual library of more than 44 million covalent compounds combining SPC-branded monomers with drug-like building blocks and covalent warheads.

13GlueSpace
CategoryVirtual compound library
Description

Virtual library of more than 95 million CRBN-binding molecules combining CRBN-binding monomers with drug-like building blocks for molecular glue drug discovery.

14Scaffolds
CategoryCompound collection
Description

3D scaffolds for DNA-Encoded Libraries (DEL) featuring bi- and tri-functionalized designs with uncharted chemical space and orthogonal protecting groups.

15Consulting Services
CategoryConsulting services
Description

Expert chemistry consulting including literature analysis, SAR analysis, strategy proposals, retrosynthetic analysis, patent gap analysis, and patent filing support, billed hourly, daily or project-based.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-06-06
Description

SpiroChem acquired Montreal-based Cyclenium Pharma on June 6, 2023. The acquisition expanded SpiroChem's capabilities in macrocyclic therapeutics and established its first research foothold in North America. Cyclenium brought recognized expertise in macrocycles, a specialized modality requiring deep scientific know-how, into SpiroChem's growing platform.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major global CRO/CDMO offering discovery services, safety assessment, and manufacturing. Acquires specialty chemistry capabilities and competes for pharma/biotech discovery outsourcing budgets.

TypeDirect peer
Description

UK-based, ~500-scientist discovery chemistry CRO offering FTE medicinal chemistry, computational chemistry, and DMPK to pharma and biotech. Closest direct comparable to SpiroChem's PRO-style discovery model and customer mix, though larger in scale.

TypeDirect peer
Description

Poland-headquartered CRO with medicinal chemistry, computational chemistry, and integrated discovery services serving biotech and pharma globally. Comparable horizontal CRO model with similar target customers.

TypeDirect peer
Description

China-founded, globally operating CRO/CDMO with strong medicinal chemistry, FTE discovery services, and integrated discovery offerings. Direct competitor for outsourced medicinal chemistry and discovery chemistry FTE contracts.

TypeDirect peer
Description

Integrated discovery CRO with significant medicinal and synthetic chemistry capacity serving biotech and pharma. Closely comparable in offering FTE-based discovery chemistry and custom synthesis.

TypeBroad incumbent
Description

Large Hamburg-based drug discovery CRO/CDMO with a 'Partner Research Organization' model very similar to SpiroChem's positioning, plus shared-economy partnerships (e.g., LAB150). Larger scale but the most strategically analogous peer.

TypeBroad incumbent
Description

China-headquartered, globally integrated CRO/CDMO with strong synthetic/medicinal chemistry services, process R&D, and manufacturing — competing for outsourced chemistry at all stages.

TypeBroad incumbent
Description

Largest Asia-based CRO/CDMO offering end-to-end discovery, development, and manufacturing. Competes for biotech and pharma chemistry outsourcing including complex modalities.

TypeBroad incumbent
Description

Discovery services arm of Eurofins providing medicinal chemistry, in vitro pharmacology, and ADME services to pharma and biotech. Comparable FTE-based chemistry service model.

TypeDirect peer
Description

UK-based discovery CRO with medicinal chemistry, in vitro biology, and ADME capabilities serving biotech and pharma. Closely comparable mid-sized chemistry-focused CRO peer.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers19 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile4 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature13 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

SpiroChem AG

Contract Chemistry Services / Drug Discovery Researchspirochem.com

SpiroChem AG is a Swiss chemistry research partner (ETH Zürich spin-off, founded 2011) that delivers integrated drug discovery and process R&D services — medicinal chemistry, synthetic chemistry, and complex modalities — to pharma, biotech, and academia via FTE contracts and proprietary platforms.

What SpiroChem AG does

SpiroChem AG is a Swiss specialty chemistry research company founded in 2011 as a spin-off of ETH Zürich, headquartered in Basel with a second R&D facility in Montreal (acquired 2023 via Cyclenium Pharma). The company operates as a Partner Research Organization (PRO), delivering integrated drug discovery and process R&D services — including computational chemistry, medicinal chemistry, synthetic chemistry, and specialized modalities (macrocycles, ADCs, degraders, radioligands, covalent inhibitors) — to biopharmaceutical companies, large pharma (Novartis, Asahi Kasei, H3 Biomedicine), biotech startups, agrochemical firms (Syngenta), and academic institutions.

The technical platform is built on proprietary infrastructure including the Hercules+ high-throughput parallel solid-phase synthesis platform, the HTE platform for reaction optimization, and SpiroBrain — a deep collective knowledge base spanning all chemistry disciplines. The company also maintains four virtual libraries (SpiroSpace: 105M+ sp3-rich molecules; MacroSpace: 229M+ macrocycles; CovSpace: 44M+ covalent compounds; GlueSpace: 95M+ CRBN-binding molecules) alongside physical screening libraries and SpiroKits. Enablement extends across solid-phase synthesis, flow chemistry, photochemistry, and electrochemistry. A granted process patent covers scalable manufacturing of bicyclo[1.1.1]pentanes (filed 2016).

The business model combines recurring FTE (Full-Time Equivalent) contracts — typically 1–6 dedicated chemists per program for 3–12+ months — with one-time compound catalog sales (13,000+ molecules via e-commerce) and hourly/project-based consulting. Go-to-market is direct enterprise sales supplemented by conference presence (EFMC, ACS, CPHI), the SpiroWebinars program, and scientific publication. Headcount has scaled from 20 (2018) to 50 (2020) to 60+ (2021) to 100+ by 2026, with the majority PhD chemists. The company is privately held, primarily built through reinvestment of profits rather than dilutive funding, and has not disclosed revenue.

SpiroChem AG firmographics

Firmographics
Name
SpiroChem AG
Legal name
SpiroChem AG
Website
https://spirochem.com
Company type
Private
Founded year
2011
Operating status
Operating
Headcount range
51–100 employees
Short description
SpiroChem AG is a Swiss chemistry research partner (ETH Zürich spin-off, founded 2011) that delivers integrated drug discovery and process R&D services — medicinal chemistry, synthetic chemistry, and complex modalities — to pharma, biotech, and academia via FTE contracts and proprietary platforms.
Ownership category
akta.pro rank

SpiroChem AG industry classification

Industry
Product category
Contract Chemistry Services / Drug Discovery Research
NAICS
Scientific Research and Development Services (5417), Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) (541715)
SIC
Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services

Keywords

  • Contract chemistry services
  • Drug discovery research
  • Medicinal chemistry
  • Process R&D
  • Custom synthesis

Where SpiroChem AG is headquartered

Location

Headquarters

HQ city
Basel
HQ country
Switzerland
HQ region
Europe

Offices2 records

Markets served

SpiroChem AG business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

  1. FTE (Full-Time Equivalent) Service Contracts: Recurring service contracts providing dedicated chemists working on client projects, typically 1-6 chemists per program for 3-12+ months duration. Core revenue stream for discovery and process R&D services.
  2. Compound Catalog Sales: Sale of screening libraries (macrocycles, fragments, covalent fragments, scaffolds), SpiroKits, and building blocks ranging from milligram to hundred gram scale. E-commerce enabled through company website.
  3. Consulting Services: Expert consulting including literature analysis, SAR analysis, strategy proposals, retrosynthetic analysis, patent gap analysis, and patent filing support. Billed hourly, daily, or project-based.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goStandard Shipping Rate
OtherPay-as-you-goConsulting Services
SubscriptionMonthlyFTE Contracts
Unit PricingPay-as-you-goCompound Catalog

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

SpiroChem AG product offering

Product offering

Core offering

SpiroChem AG is a Partner Research Organization (PRO) offering contract chemistry research services for drug discovery and process R&D. The company sells Full-Time Equivalent (FTE) service contracts, custom synthesis projects, compound catalog products (screening libraries and building blocks), and consulting services to biotech, pharmaceutical, agrochemical and academic clients. It also operates proprietary technology platforms (Hercules+, HTE, SpiroBrain) and virtual compound libraries (SpiroSpace, MacroSpace, CovSpace, GlueSpace) used internally and made available to clients.

Product overview

SpiroChem AG is a pioneering research partner and Discovery Engine offering integrated drug discovery and process R&D chemistry services. The company operates a platform-plus-services model centered on its core Discovery Services (computational chemistry, medicinal chemistry, synthetic chemistry, precision delivery) and Process R&D capabilities. Key platforms include the Hercules Platform for high-throughput chemistry, HTE Platform for experimentation, and SpiroBrain for collective knowledge management. The compound portfolio includes physical screening libraries (Macrocycle Library, Fragment Library, SpiroKits, Scaffolds) and virtual libraries (SpiroSpace, MacroSpace, CovSpace, GlueSpace). The company expanded through the 2023 acquisition of Cyclenium Pharma, adding macrocycle expertise and a North American R&D facility in Montreal.

Differentiator

Problem solved

Functional benefit

Brands

  • SpiroSpace™: Virtual library providing access to more than 105 million drug-like sp3-rich molecules
  • MacroSpace™
  • CovSpace™
  • GlueSpace™
  • Hercules+™
  • SpiroBrain™
  • SpiroKits™
  • SpiroWebinars

Products and services

  • Discovery Services Comprehensive drug discovery services including computational chemistry, medicinal chemistry, synthetic chemistry, and precision delivery, covering the hit-to-candidate journey for pharmaceutical and biotech clients.
  • Process R&D Process research and development services including route scouting, technology transfer, scale-up, impurity synthesis and identification, method development, and reference standards for pharma, biotech and CDMO clients.
  • Fully Integrated Services Integrated discovery services bringing together SpiroChem's trusted research partner network supporting clients from hit validation through lead optimization to early process R&D.
  • Hercules Platform High-throughput chemistry platform enabling rapid parallel synthesis and broad diversity coverage for accelerated drug discovery.
  • HTE Platform High-throughput experimentation platform for rapid optimization of chemical reactions and reaction conditions.
  • SpiroBrain Deep, collective knowledge base representing SpiroChem's expertise from all chemistry disciplines, enabling problem-solving by connecting solutions across projects.
  • Macrocycle Library Screening library of macrocyclic compounds for drug discovery, offering access to challenging biological targets with enhanced target affinity.
  • Fragment Library Collection of over 700 fragment molecules with unique design, high sp3 content, and conformationally restricted structures for fragment-based drug discovery.
  • SpiroKits Medicinal chemistry toolbox providing turnkey solutions to accelerate projects and foster chemical space exploration.
  • SpiroSpace Virtual library of more than 105 million drug-like sp3-rich molecules, built upon SpiroChem's proprietary SPC-branded monomers combined with drug-like building blocks.
  • MacroSpace Virtual collection of over 229 million distinct macrocycles with drug-like properties, created by combining three amino acids with a non-peptidic linker.
  • CovSpace Virtual library of more than 44 million covalent compounds combining SPC-branded monomers with drug-like building blocks and covalent warheads.
  • GlueSpace Virtual library of more than 95 million CRBN-binding molecules combining CRBN-binding monomers with drug-like building blocks for molecular glue drug discovery.
  • Scaffolds 3D scaffolds for DNA-Encoded Libraries (DEL) featuring bi- and tri-functionalized designs with uncharted chemical space and orthogonal protecting groups.
  • Consulting Services Expert chemistry consulting including literature analysis, SAR analysis, strategy proposals, retrosynthetic analysis, patent gap analysis, and patent filing support, billed hourly, daily or project-based.

Quantifiable outcome

  • Saved Cellestia CHF 0.5 million on drug development program through innovative medicinal chemistry
  • +1 more outcomes

Companies that use SpiroChem AG

Customer profile

Named customers19 records

Segments5 records

Ideal customer profiles4 records

SpiroChem AG technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature13 records

SpiroChem AG partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Cyclenium Pharma Inc.coreStrategic or Co-development Partner · 6 June 2023SpiroChem acquired Montreal-based Cyclenium Pharma on June 6, 2023. The acquisition expanded SpiroChem's capabilities in macrocyclic therapeutics and established its first research foothold in North America. Cyclenium brought recognized expertise in macrocycles, a specialized modality requiring deep scientific know-how, into SpiroChem's growing platform.

Scale indicators5 records

Recent moves9 records

Expansion highlights7 records

SpiroChem AG competitors and assessment

Company assessment

Broad incumbents

  • Charles River Laboratories: Major global CRO/CDMO offering discovery services, safety assessment, and manufacturing. Acquires specialty chemistry capabilities and competes for pharma/biotech discovery outsourcing budgets.
  • Evotec: Large Hamburg-based drug discovery CRO/CDMO with a 'Partner Research Organization' model very similar to SpiroChem's positioning, plus shared-economy partnerships (e.g., LAB150). Larger scale but the most strategically analogous peer.
  • Pharmaron: China-headquartered, globally integrated CRO/CDMO with strong synthetic/medicinal chemistry services, process R&D, and manufacturing — competing for outsourced chemistry at all stages.
  • WuXi AppTec / WuXi STA: Largest Asia-based CRO/CDMO offering end-to-end discovery, development, and manufacturing. Competes for biotech and pharma chemistry outsourcing including complex modalities.
  • Eurofins Discovery: Discovery services arm of Eurofins providing medicinal chemistry, in vitro pharmacology, and ADME services to pharma and biotech. Comparable FTE-based chemistry service model.

Direct peers

  • Sygnature Discovery: UK-based, ~500-scientist discovery chemistry CRO offering FTE medicinal chemistry, computational chemistry, and DMPK to pharma and biotech. Closest direct comparable to SpiroChem's PRO-style discovery model and customer mix, though larger in scale.
  • Selvita: Poland-headquartered CRO with medicinal chemistry, computational chemistry, and integrated discovery services serving biotech and pharma globally. Comparable horizontal CRO model with similar target customers.
  • ChemPartner: China-founded, globally operating CRO/CDMO with strong medicinal chemistry, FTE discovery services, and integrated discovery offerings. Direct competitor for outsourced medicinal chemistry and discovery chemistry FTE contracts.
  • BioDuro-Sundia: Integrated discovery CRO with significant medicinal and synthetic chemistry capacity serving biotech and pharma. Closely comparable in offering FTE-based discovery chemistry and custom synthesis.
  • Concept Life Sciences: UK-based discovery CRO with medicinal chemistry, in vitro biology, and ADME capabilities serving biotech and pharma. Closely comparable mid-sized chemistry-focused CRO peer.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

SpiroChem AG social profiles

Digital presence

SpiroChem AG financial estimates

Financial estimate

Revenue estimate

Valuation estimate

SpiroChem AG leadership team

Management profile

Number of profiles

Profiles15 records

SpiroChem AG subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

SpiroChem AG funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

SpiroChem AG M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about SpiroChem AG

What does SpiroChem AG do?

SpiroChem AG is a Partner Research Organization (PRO) offering contract chemistry research services for drug discovery and process R&D. The company sells Full-Time Equivalent (FTE) service contracts, custom synthesis projects, compound catalog products (screening libraries and building blocks), and consulting services to biotech, pharmaceutical, agrochemical and academic clients. It also operates proprietary technology platforms (Hercules+, HTE, SpiroBrain) and virtual compound libraries (SpiroSpace, MacroSpace, CovSpace, GlueSpace) used internally and made available to clients.

Is SpiroChem AG a public or private company?

SpiroChem AG is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was SpiroChem AG founded?

SpiroChem AG was founded in 2011. It employs 51 to 100 people.

Where is SpiroChem AG based?

SpiroChem AG is headquartered in Basel, Switzerland, in the Europe region.

How does SpiroChem AG make money?

Three revenue lines are on record. FTE (Full-Time Equivalent) Service Contracts are the primary driver. The others are compound Catalog Sales and consulting Services.

Who are SpiroChem AG's main competitors?

Broad incumbents on record are Charles River Laboratories, Evotec, Pharmaron, WuXi AppTec / WuXi STA and Eurofins Discovery. Direct peers are Sygnature Discovery, Selvita, ChemPartner, BioDuro-Sundia and Concept Life Sciences.

Does SpiroChem AG have an API?

No public API is recorded for SpiroChem AG.

What industry is SpiroChem AG in?

SpiroChem AG's product category is Contract Chemistry Services / Drug Discovery Research. Its primary akta.pro industry code is HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 5417 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chCHF 150,000 from Venture Kick to simplifiy pharmaceutical and fine chemical manufacturinghephaistos.bio, a Swiss techbio startup, received CHF 150,000 from Venture Kick to support industrial enzyme design campaigns and lab automation. The company develops custom protein catalysts to replace energy-intensive chemical processes, aiming to reduce manufacturing costs by up to 30% and CO₂ emissions by up to 50%.Business Wire BlogEUROAPI Enhances Its CDMO Capabilities Through a Pivotal Collaboration With SpiroChem, a Leading Contract Research Organization (CRO)EUROAPI announced a collaboration with SpiroChem to offer consolidated CRO-CDMO solutions for API development. The partnership integrates SpiroChem's route scouting with EUROAPI's industrialization and GMP manufacturing, aiming to shorten timelines for early-stage projects and biotech clients.startupticker.chSpirochem acquires Canadian biotech companySpiroChem, a Contract Research Organization based in Basel, has acquired Cyclenium Pharma, a Canadian biotech company specializing in macrocyclic therapeutics. This acquisition allows SpiroChem to expand its capabilities in drug discovery and establish a stronger presence in the North American market. The combined entity aims to leverage synergies between their respective technologies to create novel opportunities for hit generation and development projects.SpirochemSpiroChem Acquires Cyclenium Pharma to Strengthen its Portfolio in Macrocyclic TherapeuticsSpiroChem announced the acquisition of Cyclenium Pharma to expand its capabilities in macrocyclic therapeutics and strengthen its presence in North America. This strategic move combines SpiroChem's expertise in conformationally restricted motifs with Cyclenium's CMRT™ technology platform to create novel drug discovery libraries. The integration aims to leverage diverse talent pools in Montreal and enhance operations in Basel.startupticker.chSpirochem completes fundraise to support accelerated growthSpiroChem AG completed a fundraise to invest in accelerated growth, with net proceeds used to scale sales and productivity via state-of-the-art equipment. The company relocated to new facilities in Basel and expects continued demand from its customer base.